V-Rel Reticuloendotheliosis Viral Oncogene Homolog A, Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 3, P65 (RELA) (pS536) Antikörper

Antigen: V-Rel Reticuloendotheliosis Viral Oncogene Homolog A, Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 3, P65 (RELA)

Synonyme: p50, KBF1, p105, EBP-1, MGC54151, NFKB-p50, NF-kappaB, NFKB-p105, NF-kappa-B, DKFZp686C01211, NF-kB, NF-KB1, Xrel1, nfkb3, xrela, MGC69459, NFKB1, kbf1, ebp-1, MGC86262, nfkb-p50, nf-kappaB, nfkb-p105, nf-kappa-b, RELA, p65, NFKB3, MGC131774

Epitope: pS536

Klonalität: Polyklonal

Wirt: Kaninchen

Reaktivität: Human, Rind (Kuh), Maus, Ratte (Rattus)

Applikation: Immunhistochemie (IHC), ELISA, Western Blot (WB), Immunpräzipitation (IP)

Produktnummer: ABIN129575

Produktbeschreibung

Weitere Bezeichnung: Np65 (NFkB) (Rel A) phospho specific pS536

Swiss-Prot: Q04206

Immunogen: This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to residues surrounding S536 of human p65 (RelA) protein.

Format: Liquid (sterile filtered)

Beschreibung: NF kappa B was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NF kappa B bound to I kappa B. NF kappa B was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), cRel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NF kappa B subunit p65, similar to p50/p65 heterodimers. Lowlevels of p52 and p50 homodimers can also exist in cells. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by I kappa B-alpha . I kappa B-alpha binds to the p65 subunit, preventing nuclear localization, and DNA binding. Activators mediate a rapid phosphorylation of I kappa B by I kappa B kinase (IKK), which results in subsequent ubiquitination and proteolytic degradation. NF kappa B is then transported to the nucleus, where it activates transcription of target genes through binding to NF kappa B target sequences within the promoter. The HTLV-I protein Tax can induce constitutive NF kappa B activation through phosphorylation of both I kappa B-alpha and I kappa B- beta . The transforming protein Tax inhibits p53 transcriptional activity through the NF kappa B signaling pathway, specifically via the p65 (RelA) subunit. The inhibition of p53 activity is dependent upon phosphorylation of p65 (RelA) at S536 by the upstream kinase IKK beta .

Spezifität: This product was affinity purified from monospecific antiserum by immunoaffinity chromatography using phospho-peptide coupled to agarose beads followed by solid phase adsorption against nonphospho-peptide. This antibody is specific for human p65 (RelA) protein phosphorylated at S536. A BLAST analysis was used to suggest cross reactivity with p65 (RelA) from human, mouse and rat based on 100% homology with the immunizing sequence. Cross reactivity with p65 (RelA) from other sources has not been determined.

Synonyme: p50, KBF1, p105, EBP-1, MGC54151, NFKB-p50, NF-kappaB, NFKB-p105, NF-kappa-B, DKFZp686C01211, NF-kB, NF-KB1, Xrel1, nfkb3, xrela, MGC69459, NFKB1, kbf1, ebp-1, MGC86262, nfkb-p50, nf-kappaB, nfkb-p105, nf-kappa-b, RELA, p65, NFKB3, MGC131774

Anwendungen

Applikationshinweise: Recommended Dilutions: ELISA 1:1,000 - 1:6,000 WESTERN BLOT 1:200 - 1:2,000 IMMUNOHISTOCHEMISTRY 5 ug/ml OTHER APPLICATIONS User Optimized. Note: This affinity purified antibody has been tested for use in ELISA, immunohistochemistry and western blotting. Specific conditions for reactivity should be optimized by the end user. By western blot, a band approximately 65 kDa in size corresponding to phosphorylated p65 (RelA) protein is expected in the appropriate cell lysate or extract. This phospho-specific polyclonal antibody reacts with human p65 (RelA) pS536 and shows minimal reactivity by western blot with non-phosphorylated p65 (RelA) and minimal reactivity by ELISA against the non-phosphorylated form of the immunizing peptide.

Konzentration: 0.9 mg/ml (by UV absorbance at 280 nm)

Buffer: Stabilizer: None. Preservative: 0.01% (w/v) Sodium Azide. Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2.

Lagerung: Store vial at -20° C or below prior to opening. Dilute only prior to immediate use. For extended storage, aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Expiration date is one (1) year from date of opening.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Bilder

Immunohistochemistry. antibodies-online's affinity purified anti-p65 (RelA) pS536 antibody was used at 5.0 ug/ml to detect signal in a variety of tissues including multi-human, multi-brain and multi-cancer slides. This image shows moderate positive staining of human kidney distal tubules and collecting ducts. Tissue was formalin-fixed and paraffin embedded. The image shows localization of the antibody as the precipitated red signal, with a hematoxylin purple nuclear counterstain. Personal Communication, Tina Roush, LifeSpanBiosciences, Seattle, WA.